| Identification | Back Directory | [Name]
1-O-HEXADECYL-(7,7,8,8-D4)-SN-GLYCERYL-3-PHOSPHORYLCHOLINE | [CAS]
201216-37-7 | [Synonyms]
LYSO-PAF C-16-D4
VLBPIWYTPAXCFJ-OAJQLNMKSA-N
1-O-HEXADECYL-(7,7,8,8-D4)-SN-GLYCERYL-3-PHOSPHORYLCHOLINE | [Molecular Formula]
C24H52NO6P | [MDL Number]
MFCD00084829 | [MOL File]
201216-37-7.mol | [Molecular Weight]
481.65 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml,DMSO: 10 mg/ml,Ethanol: 10 mg/ml,PBS (pH 7.2): 10 mg/ml | [form ]
Liquid | [color ]
Colorless to light yellow | [Water Solubility ]
Water: 20 mg/ml |
| Hazard Information | Back Directory | [Description]
Lyso-PAF C-16-d4 contains four deuterium atoms at the 7, 7'', 8, and 8'' positions of the hexadecyl moiety. It is intended for use as an internal standard for the quantification of PAF C-16 by GC- or LC-mass spectrometry. Lyso-PAF C-16 can be formed by either the action of PAF-AH on PAF C-16, or by the action of a CoA-independent transacylase on 1-O-hexadecyl-2-acyl-glycerophosphocholine. Lyso-PAF C-16 is a substrate for either PAF C-16 formation by the remodeling pathway or selective acylation with arachidonic acid by a CoA-independent transacylase. | [Uses]
Lyso-PAF C-16-d4 is the deuterium labeled Lyso-PAF C-16[1]. | [Definition]
ChEBI: Lyso-PAF C-16-d4 is a monoalkylglycerophosphocholine. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110 |
|
| Company Name: |
Boao Pike
|
| Tel: |
010-57798038 15652371397 |
| Website: |
www.biopike.cn |
| Company Name: |
Resenbio
|
| Tel: |
029-86354885 |
| Website: |
www.xarxbio.com |
|